Cargando…

Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges

“Cast nephropathy” (CN) is a pathological feature of myeloma kidney, also seen to a lesser extent in the context of severe nephrotic syndrome from non-haematological diseases. The name relates to obstruction of distal tubules by “casts” of luminal proteins concentrated by intensive water reabsorptio...

Descripción completa

Detalles Bibliográficos
Autores principales: Menè, Paolo, Stoppacciaro, Antonella, Lai, Silvia, Festuccia, Francescaromana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113496/
https://www.ncbi.nlm.nih.gov/pubmed/35592304
http://dx.doi.org/10.2147/IJNRD.S280179
_version_ 1784709595508244480
author Menè, Paolo
Stoppacciaro, Antonella
Lai, Silvia
Festuccia, Francescaromana
author_facet Menè, Paolo
Stoppacciaro, Antonella
Lai, Silvia
Festuccia, Francescaromana
author_sort Menè, Paolo
collection PubMed
description “Cast nephropathy” (CN) is a pathological feature of myeloma kidney, also seen to a lesser extent in the context of severe nephrotic syndrome from non-haematological diseases. The name relates to obstruction of distal tubules by “casts” of luminal proteins concentrated by intensive water reabsorption resulting from dehydration or high-dose diuretics. Filtered proteins form complexes with endogenous tubular Tamm-Horsfall glycoprotein. The resulting gel further slows or stops luminal flow upon complete obstruction of distal convoluted tubules and collecting ducts. Thus, a tubular obstructive form of acute kidney injury (AKI) is a common consequence of CN. The pathogenesis of CN will be reviewed in light of recent advances in the understanding of monoclonal disorders of B lymphocytes, leading to the release of immunoglobulin components (free light chains, FLC) into the bloodstream and their filtration across the glomerular basement membrane. Treatment aiming at reduction of the circulating burden of FLC may help recovery of renal function in a fraction of these patients, besides filling the void between the onset of AKI, histopathological diagnosis, and full response to pharmacologic treatment.
format Online
Article
Text
id pubmed-9113496
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-91134962022-05-18 Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges Menè, Paolo Stoppacciaro, Antonella Lai, Silvia Festuccia, Francescaromana Int J Nephrol Renovasc Dis Review “Cast nephropathy” (CN) is a pathological feature of myeloma kidney, also seen to a lesser extent in the context of severe nephrotic syndrome from non-haematological diseases. The name relates to obstruction of distal tubules by “casts” of luminal proteins concentrated by intensive water reabsorption resulting from dehydration or high-dose diuretics. Filtered proteins form complexes with endogenous tubular Tamm-Horsfall glycoprotein. The resulting gel further slows or stops luminal flow upon complete obstruction of distal convoluted tubules and collecting ducts. Thus, a tubular obstructive form of acute kidney injury (AKI) is a common consequence of CN. The pathogenesis of CN will be reviewed in light of recent advances in the understanding of monoclonal disorders of B lymphocytes, leading to the release of immunoglobulin components (free light chains, FLC) into the bloodstream and their filtration across the glomerular basement membrane. Treatment aiming at reduction of the circulating burden of FLC may help recovery of renal function in a fraction of these patients, besides filling the void between the onset of AKI, histopathological diagnosis, and full response to pharmacologic treatment. Dove 2022-05-13 /pmc/articles/PMC9113496/ /pubmed/35592304 http://dx.doi.org/10.2147/IJNRD.S280179 Text en © 2022 Menè et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Menè, Paolo
Stoppacciaro, Antonella
Lai, Silvia
Festuccia, Francescaromana
Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges
title Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges
title_full Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges
title_fullStr Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges
title_full_unstemmed Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges
title_short Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges
title_sort light chain cast nephropathy in multiple myeloma: prevalence, impact and management challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113496/
https://www.ncbi.nlm.nih.gov/pubmed/35592304
http://dx.doi.org/10.2147/IJNRD.S280179
work_keys_str_mv AT menepaolo lightchaincastnephropathyinmultiplemyelomaprevalenceimpactandmanagementchallenges
AT stoppacciaroantonella lightchaincastnephropathyinmultiplemyelomaprevalenceimpactandmanagementchallenges
AT laisilvia lightchaincastnephropathyinmultiplemyelomaprevalenceimpactandmanagementchallenges
AT festucciafrancescaromana lightchaincastnephropathyinmultiplemyelomaprevalenceimpactandmanagementchallenges